EMA Recommends Extension of Indications for Pirtobrutinib By Ogkologos - April 24, 2025 846 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Nivolumab vs Sorafenib in First-Line Treatment of Advanced Hepatocellular Carcinoma July 1, 2020 No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk... June 22, 2026 What Cancer Caregivers Should Know About Hospice Care at Home: A... August 31, 2021 ΟΡΘΟΚΟΛΙΚΟΣ ΚΑΡΚΙΝΟΣ February 7, 2019 Load more HOT NEWS EMA Recommends Extension of Indications for Dostarlimab “White Bagging” Harmful to Patients, Requires Them to Use Insurance-Approved Formulary... ESMO Releases New Patient Guide in Hepatocellular Carcinoma 10 Things I Wish I Knew When I Was First Diagnosed...
